Not all patients will benefit from I-O
a
>100%. Several patients with CR had <100% reduction due to lymph node target lesions.
Lymph nodes returned to normal size per RECIST v1.1.
b
Per IRF RECIST v1.1;
Median follow-up:17.5 months; data cut-off: 14 March 2016
Maximum SLD reduction from baseline (%)
RECIST v1.1 status
PD SD PR CR NE
IC2/3; 28% ORR
b
100
–100
0
a
